ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Cell-free plasma DNA-guided treatment with osimertinib in patients with advanced EGFR-mutated NSCLC.

Buder Anna; Hochmair Maximilian J; Schwab Sophia; Bundalo Tatjana; Schenk Peter; Errhalt Peter; Mikes Romana E; Absenger Gudrun; Patocka Kurt; Baumgartner Bernhard; Setinek Ulrike; Burghuber Otto C; Prosch Helmut; Pirker Robert; Filipits Martin*
Journal of Thoracic Oncology2018-3-2DOI: 10.1016/j.jtho.2018.02.014
6阅读
引用收藏
分享

摘要

INTRODUCTION: Osimertinib is standard treatment for patients with advanced EGFR T790M-mutated NSCLC who have been pre-treated with EGFR-TKIs. We studied whether cell-free plasma DNA for T790M detection can be used to select patients for osimertinib treatment in clinical routine. METHODS: From April 2015 to November 2016, we included 119 patients with advanced EGFR-mutated NSCLC who had progressed under treatment with an EGFR-TKI. The T790M mutation status was assessed in cell-free plasma DNA by droplet digital PCR (ddPCR) in all patients and by tissue analyses in selected patients. RESULTS: T790M mutations were detected in 85 (93%) patients by analyses of cell-free plasma DNA and in 6 (7%) plasma-negative patients by tumor re-biopsy. Eighty-nine out of the 91 T790M-positive patients received osimertinib. Median progression-free survival (PFS) was 10.1 months (95% CI 8.1-12.1). Median survival was not reached and the 1-year survival was 64%. The response rate (RR) was 70% in T790M-positive patients (n=91) in the intention-to-treat population. PFS trended to be longer in patients with low T790M copy number (<10 copies/mL) compared to those with high T790M copy number (>/=10 copies/mL) (hazard ratio [HR] for PFS 1.72, 95% confidence interval [CI] 0.92-3.2, p=0.09). A comparable trend was observed for overall survival (HR for OS 2.16, 95% CI 0.89-5.25, p=0.09). No difference in RR was observed based on T790M copy numbers. CONCLUSIONS: Plasma genotyping using ddPCR is clinically useful for the selection of patients who had progressed during first-line EGFR-TKI therapy for treatment with osimertinib.

相关
加载中…

文献加载失败,请重试

重试

发表信息

论文状态
公开发表
期刊
Journal of Thoracic Oncology
发表日期
2018-03-02
DOI
10.1016/j.jtho.2018.02.014
语言
ENGLISH
期刊等级
Q1
成果收录
PUBMED

作者

  • B

    Buder Anna (第一作者)

  • H

    Hochmair Maximilian J

查看全部 15 位作者收起作者
  • S

    Schwab Sophia

  • B

    Bundalo Tatjana

  • S

    Schenk Peter

  • E

    Errhalt Peter

  • M

    Mikes Romana E

  • A

    Absenger Gudrun

  • P

    Patocka Kurt

  • B

    Baumgartner Bernhard

  • S

    Setinek Ulrike

  • B

    Burghuber Otto C

  • P

    Prosch Helmut

  • P

    Pirker Robert

  • F

    Filipits Martin (通讯)

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417